nodes	percent_of_prediction	percent_of_DWPC	metapath
Sorafenib—HTR2B—Raloxifene—osteoporosis	0.0524	0.0962	CbGbCtD
Sorafenib—ABCC4—Conjugated Estrogens—osteoporosis	0.0397	0.0728	CbGbCtD
Sorafenib—UGT1A1—Estradiol—osteoporosis	0.0341	0.0625	CbGbCtD
Sorafenib—ABCC2—Ethinyl Estradiol—osteoporosis	0.0322	0.059	CbGbCtD
Sorafenib—ABCC2—Conjugated Estrogens—osteoporosis	0.0236	0.0433	CbGbCtD
Sorafenib—ABCG2—Conjugated Estrogens—osteoporosis	0.0214	0.0392	CbGbCtD
Sorafenib—CYP2B6—Raloxifene—osteoporosis	0.0212	0.0389	CbGbCtD
Sorafenib—CYP2B6—Ethinyl Estradiol—osteoporosis	0.0205	0.0375	CbGbCtD
Sorafenib—ABCG2—Estradiol—osteoporosis	0.0187	0.0344	CbGbCtD
Sorafenib—CYP1A2—Estropipate—osteoporosis	0.0186	0.0341	CbGbCtD
Sorafenib—CYP2C9—Estropipate—osteoporosis	0.0168	0.0308	CbGbCtD
Sorafenib—CYP2B6—Cholecalciferol—osteoporosis	0.0164	0.03	CbGbCtD
Sorafenib—CYP2C8—Raloxifene—osteoporosis	0.016	0.0294	CbGbCtD
Sorafenib—CYP2C8—Ethinyl Estradiol—osteoporosis	0.0155	0.0284	CbGbCtD
Sorafenib—CYP3A7—Estradiol—osteoporosis	0.0138	0.0254	CbGbCtD
Sorafenib—CYP3A7-CYP3A51P—Estradiol—osteoporosis	0.0138	0.0254	CbGbCtD
Sorafenib—CYP2C8—Cholecalciferol—osteoporosis	0.0124	0.0227	CbGbCtD
Sorafenib—ABCB1—Ethinyl Estradiol—osteoporosis	0.0105	0.0192	CbGbCtD
Sorafenib—CYP2C19—Cholecalciferol—osteoporosis	0.0104	0.0191	CbGbCtD
Sorafenib—CYP3A5—Estradiol—osteoporosis	0.0104	0.0191	CbGbCtD
Sorafenib—CYP2C8—Estradiol—osteoporosis	0.00999	0.0183	CbGbCtD
Sorafenib—CYP3A4—Estropipate—osteoporosis	0.00975	0.0179	CbGbCtD
Sorafenib—CYP3A4—Calcitriol—osteoporosis	0.00975	0.0179	CbGbCtD
Sorafenib—CYP1A2—Conjugated Estrogens—osteoporosis	0.00881	0.0162	CbGbCtD
Sorafenib—CYP2C9—Cholecalciferol—osteoporosis	0.00864	0.0159	CbGbCtD
Sorafenib—CYP2C19—Estradiol—osteoporosis	0.00838	0.0154	CbGbCtD
Sorafenib—CYP2D6—Cholecalciferol—osteoporosis	0.0079	0.0145	CbGbCtD
Sorafenib—CYP3A4—Ergocalciferol—osteoporosis	0.0078	0.0143	CbGbCtD
Sorafenib—CYP1A2—Estradiol—osteoporosis	0.00773	0.0142	CbGbCtD
Sorafenib—ABCB1—Conjugated Estrogens—osteoporosis	0.0077	0.0141	CbGbCtD
Sorafenib—CYP2C9—Estradiol—osteoporosis	0.00697	0.0128	CbGbCtD
Sorafenib—ABCB1—Estradiol—osteoporosis	0.00676	0.0124	CbGbCtD
Sorafenib—CYP3A4—Raloxifene—osteoporosis	0.00651	0.0119	CbGbCtD
Sorafenib—CYP3A4—Ethinyl Estradiol—osteoporosis	0.00629	0.0115	CbGbCtD
Sorafenib—CYP3A4—Cholecalciferol—osteoporosis	0.00502	0.00922	CbGbCtD
Sorafenib—RET—parathyroid gland—osteoporosis	0.00467	0.137	CbGeAlD
Sorafenib—CYP3A4—Conjugated Estrogens—osteoporosis	0.00461	0.00846	CbGbCtD
Sorafenib—CSF1R—periosteum—osteoporosis	0.00423	0.124	CbGeAlD
Sorafenib—CYP3A4—Estradiol—osteoporosis	0.00405	0.00743	CbGbCtD
Sorafenib—MKNK1—Estradiol—Estropipate—osteoporosis	0.00141	0.418	CbGdCrCtD
Sorafenib—CDK7—uterus—osteoporosis	0.00138	0.0406	CbGeAlD
Sorafenib—ZAK—uterus—osteoporosis	0.00119	0.0351	CbGeAlD
Sorafenib—TIE1—uterus—osteoporosis	0.00109	0.0321	CbGeAlD
Sorafenib—MKNK1—Estradiol—Conjugated Estrogens—osteoporosis	0.00107	0.317	CbGdCrCtD
Sorafenib—BRAF—uterus—osteoporosis	0.00105	0.0308	CbGeAlD
Sorafenib—EPHX2—uterus—osteoporosis	0.001	0.0294	CbGeAlD
Sorafenib—HIPK3—bone marrow—osteoporosis	0.000991	0.0291	CbGeAlD
Sorafenib—MKNK1—Estradiol—Ethinyl Estradiol—osteoporosis	0.000895	0.266	CbGdCrCtD
Sorafenib—FGFR1—uterus—osteoporosis	0.00089	0.0262	CbGeAlD
Sorafenib—BRAF—bone marrow—osteoporosis	0.000888	0.0261	CbGeAlD
Sorafenib—FLT3—bone marrow—osteoporosis	0.000843	0.0248	CbGeAlD
Sorafenib—MAP3K7—uterus—osteoporosis	0.000842	0.0248	CbGeAlD
Sorafenib—MKNK2—uterus—osteoporosis	0.000816	0.024	CbGeAlD
Sorafenib—FLT4—bone marrow—osteoporosis	0.000765	0.0225	CbGeAlD
Sorafenib—RALBP1—uterus—osteoporosis	0.000737	0.0217	CbGeAlD
Sorafenib—MAP3K7—bone marrow—osteoporosis	0.000715	0.021	CbGeAlD
Sorafenib—FLT1—uterus—osteoporosis	0.000701	0.0206	CbGeAlD
Sorafenib—RAF1—uterus—osteoporosis	0.000697	0.0205	CbGeAlD
Sorafenib—MKNK2—bone marrow—osteoporosis	0.000693	0.0204	CbGeAlD
Sorafenib—MKNK1—bone marrow—osteoporosis	0.000684	0.0201	CbGeAlD
Sorafenib—STK10—uterus—osteoporosis	0.000664	0.0195	CbGeAlD
Sorafenib—PDGFRA—uterus—osteoporosis	0.000657	0.0193	CbGeAlD
Sorafenib—RALBP1—bone marrow—osteoporosis	0.000626	0.0184	CbGeAlD
Sorafenib—KDR—uterus—osteoporosis	0.000593	0.0174	CbGeAlD
Sorafenib—RAF1—bone marrow—osteoporosis	0.000592	0.0174	CbGeAlD
Sorafenib—CSF1R—uterus—osteoporosis	0.000578	0.017	CbGeAlD
Sorafenib—STK10—bone marrow—osteoporosis	0.000563	0.0166	CbGeAlD
Sorafenib—KIT—uterus—osteoporosis	0.000525	0.0154	CbGeAlD
Sorafenib—PDGFRB—uterus—osteoporosis	0.000513	0.0151	CbGeAlD
Sorafenib—KDR—bone marrow—osteoporosis	0.000503	0.0148	CbGeAlD
Sorafenib—CSF1R—bone marrow—osteoporosis	0.000491	0.0144	CbGeAlD
Sorafenib—KIT—bone marrow—osteoporosis	0.000446	0.0131	CbGeAlD
Sorafenib—PDGFRB—bone marrow—osteoporosis	0.000435	0.0128	CbGeAlD
Sorafenib—ABCC4—uterus—osteoporosis	0.000408	0.012	CbGeAlD
Sorafenib—HTR2B—uterus—osteoporosis	0.000406	0.0119	CbGeAlD
Sorafenib—ABCC4—bone marrow—osteoporosis	0.000347	0.0102	CbGeAlD
Sorafenib—ABCG2—uterus—osteoporosis	0.000288	0.00848	CbGeAlD
Sorafenib—ABCG2—bone marrow—osteoporosis	0.000245	0.00719	CbGeAlD
Sorafenib—Body temperature increased—Raloxifene—osteoporosis	0.000162	0.000707	CcSEcCtD
Sorafenib—Urticaria—Ibandronate—osteoporosis	0.000161	0.000703	CcSEcCtD
Sorafenib—Abdominal pain—Ibandronate—osteoporosis	0.00016	0.0007	CcSEcCtD
Sorafenib—Body temperature increased—Ibandronate—osteoporosis	0.00016	0.0007	CcSEcCtD
Sorafenib—Syncope—Zoledronate—osteoporosis	0.000159	0.000696	CcSEcCtD
Sorafenib—Leukopenia—Zoledronate—osteoporosis	0.000159	0.000695	CcSEcCtD
Sorafenib—Anaphylactic shock—Pamidronate—osteoporosis	0.000159	0.000693	CcSEcCtD
Sorafenib—Haemoglobin—Estradiol—osteoporosis	0.000158	0.000691	CcSEcCtD
Sorafenib—Infection—Pamidronate—osteoporosis	0.000158	0.000689	CcSEcCtD
Sorafenib—Urticaria—Calcitriol—osteoporosis	0.000158	0.000688	CcSEcCtD
Sorafenib—Haemorrhage—Estradiol—osteoporosis	0.000157	0.000687	CcSEcCtD
Sorafenib—Abdominal pain—Calcitriol—osteoporosis	0.000157	0.000685	CcSEcCtD
Sorafenib—Body temperature increased—Calcitriol—osteoporosis	0.000157	0.000685	CcSEcCtD
Sorafenib—Angioedema—Conjugated Estrogens—osteoporosis	0.000156	0.000683	CcSEcCtD
Sorafenib—Shock—Pamidronate—osteoporosis	0.000156	0.000682	CcSEcCtD
Sorafenib—Loss of consciousness—Zoledronate—osteoporosis	0.000156	0.000682	CcSEcCtD
Sorafenib—Hypersensitivity—Estropipate—osteoporosis	0.000156	0.00068	CcSEcCtD
Sorafenib—Nervous system disorder—Pamidronate—osteoporosis	0.000156	0.00068	CcSEcCtD
Sorafenib—Thrombocytopenia—Pamidronate—osteoporosis	0.000155	0.000679	CcSEcCtD
Sorafenib—Urinary tract disorder—Estradiol—osteoporosis	0.000155	0.000679	CcSEcCtD
Sorafenib—Vomiting—Etidronic acid—osteoporosis	0.000155	0.000678	CcSEcCtD
Sorafenib—Cough—Zoledronate—osteoporosis	0.000155	0.000677	CcSEcCtD
Sorafenib—Connective tissue disorder—Estradiol—osteoporosis	0.000154	0.000675	CcSEcCtD
Sorafenib—Urethral disorder—Estradiol—osteoporosis	0.000154	0.000674	CcSEcCtD
Sorafenib—Rash—Etidronic acid—osteoporosis	0.000154	0.000673	CcSEcCtD
Sorafenib—Dermatitis—Etidronic acid—osteoporosis	0.000154	0.000672	CcSEcCtD
Sorafenib—Syncope—Conjugated Estrogens—osteoporosis	0.000153	0.00067	CcSEcCtD
Sorafenib—Hypertension—Zoledronate—osteoporosis	0.000153	0.00067	CcSEcCtD
Sorafenib—Hypersensitivity—Alendronate—osteoporosis	0.000153	0.00067	CcSEcCtD
Sorafenib—Headache—Etidronic acid—osteoporosis	0.000153	0.000668	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Risedronate—osteoporosis	0.000152	0.000665	CcSEcCtD
Sorafenib—Asthenia—Estropipate—osteoporosis	0.000152	0.000662	CcSEcCtD
Sorafenib—Anorexia—Pamidronate—osteoporosis	0.000151	0.000661	CcSEcCtD
Sorafenib—Arthralgia—Zoledronate—osteoporosis	0.000151	0.000661	CcSEcCtD
Sorafenib—Myalgia—Zoledronate—osteoporosis	0.000151	0.000661	CcSEcCtD
Sorafenib—Loss of consciousness—Conjugated Estrogens—osteoporosis	0.00015	0.000657	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Zoledronate—osteoporosis	0.00015	0.000656	CcSEcCtD
Sorafenib—Pruritus—Estropipate—osteoporosis	0.000149	0.000653	CcSEcCtD
Sorafenib—Asthenia—Alendronate—osteoporosis	0.000149	0.000652	CcSEcCtD
Sorafenib—Hypersensitivity—Ibandronate—osteoporosis	0.000149	0.000652	CcSEcCtD
Sorafenib—Cough—Conjugated Estrogens—osteoporosis	0.000149	0.000652	CcSEcCtD
Sorafenib—Dyspnoea—Risedronate—osteoporosis	0.000149	0.00065	CcSEcCtD
Sorafenib—Erythema multiforme—Estradiol—osteoporosis	0.000149	0.00065	CcSEcCtD
Sorafenib—Dry mouth—Zoledronate—osteoporosis	0.000148	0.000646	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Ethinyl Estradiol—osteoporosis	0.000148	0.000646	CcSEcCtD
Sorafenib—Fatigue—Ethinyl Estradiol—osteoporosis	0.000148	0.000645	CcSEcCtD
Sorafenib—Pruritus—Alendronate—osteoporosis	0.000147	0.000643	CcSEcCtD
Sorafenib—Dyspepsia—Risedronate—osteoporosis	0.000147	0.000642	CcSEcCtD
Sorafenib—Tinnitus—Estradiol—osteoporosis	0.000147	0.000641	CcSEcCtD
Sorafenib—Constipation—Ethinyl Estradiol—osteoporosis	0.000146	0.00064	CcSEcCtD
Sorafenib—Hypersensitivity—Calcitriol—osteoporosis	0.000146	0.000638	CcSEcCtD
Sorafenib—Flushing—Estradiol—osteoporosis	0.000146	0.000638	CcSEcCtD
Sorafenib—Cardiac disorder—Estradiol—osteoporosis	0.000146	0.000638	CcSEcCtD
Sorafenib—Arthralgia—Conjugated Estrogens—osteoporosis	0.000146	0.000636	CcSEcCtD
Sorafenib—Myalgia—Conjugated Estrogens—osteoporosis	0.000146	0.000636	CcSEcCtD
Sorafenib—Asthenia—Ibandronate—osteoporosis	0.000145	0.000635	CcSEcCtD
Sorafenib—Nausea—Etidronic acid—osteoporosis	0.000145	0.000634	CcSEcCtD
Sorafenib—Anaphylactic shock—Zoledronate—osteoporosis	0.000145	0.000633	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—osteoporosis	0.000145	0.000632	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Pamidronate—osteoporosis	0.000145	0.000632	CcSEcCtD
Sorafenib—Diarrhoea—Estropipate—osteoporosis	0.000145	0.000632	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Risedronate—osteoporosis	0.000144	0.00063	CcSEcCtD
Sorafenib—Infection—Zoledronate—osteoporosis	0.000144	0.000629	CcSEcCtD
Sorafenib—Fatigue—Risedronate—osteoporosis	0.000144	0.000629	CcSEcCtD
Sorafenib—Pruritus—Ibandronate—osteoporosis	0.000143	0.000626	CcSEcCtD
Sorafenib—Pain—Risedronate—osteoporosis	0.000143	0.000624	CcSEcCtD
Sorafenib—Constipation—Risedronate—osteoporosis	0.000143	0.000624	CcSEcCtD
Sorafenib—Angiopathy—Estradiol—osteoporosis	0.000143	0.000623	CcSEcCtD
Sorafenib—Shock—Zoledronate—osteoporosis	0.000143	0.000623	CcSEcCtD
Sorafenib—Diarrhoea—Alendronate—osteoporosis	0.000142	0.000622	CcSEcCtD
Sorafenib—Asthenia—Calcitriol—osteoporosis	0.000142	0.000622	CcSEcCtD
Sorafenib—ABCB1—uterus—osteoporosis	0.000142	0.00418	CbGeAlD
Sorafenib—Nervous system disorder—Zoledronate—osteoporosis	0.000142	0.000621	CcSEcCtD
Sorafenib—Immune system disorder—Estradiol—osteoporosis	0.000142	0.000621	CcSEcCtD
Sorafenib—Thrombocytopenia—Zoledronate—osteoporosis	0.000142	0.00062	CcSEcCtD
Sorafenib—Mediastinal disorder—Estradiol—osteoporosis	0.000142	0.000619	CcSEcCtD
Sorafenib—Dyspnoea—Pamidronate—osteoporosis	0.000141	0.000618	CcSEcCtD
Sorafenib—Skin disorder—Zoledronate—osteoporosis	0.000141	0.000615	CcSEcCtD
Sorafenib—Pruritus—Calcitriol—osteoporosis	0.00014	0.000613	CcSEcCtD
Sorafenib—Gastrointestinal pain—Ethinyl Estradiol—osteoporosis	0.00014	0.000612	CcSEcCtD
Sorafenib—Diarrhoea—Raloxifene—osteoporosis	0.00014	0.000612	CcSEcCtD
Sorafenib—Dyspepsia—Pamidronate—osteoporosis	0.00014	0.00061	CcSEcCtD
Sorafenib—Dizziness—Estropipate—osteoporosis	0.00014	0.00061	CcSEcCtD
Sorafenib—Anaphylactic shock—Conjugated Estrogens—osteoporosis	0.00014	0.00061	CcSEcCtD
Sorafenib—Alopecia—Estradiol—osteoporosis	0.000139	0.000607	CcSEcCtD
Sorafenib—Infection—Conjugated Estrogens—osteoporosis	0.000139	0.000606	CcSEcCtD
Sorafenib—Diarrhoea—Ibandronate—osteoporosis	0.000139	0.000606	CcSEcCtD
Sorafenib—Anorexia—Zoledronate—osteoporosis	0.000138	0.000604	CcSEcCtD
Sorafenib—Decreased appetite—Pamidronate—osteoporosis	0.000138	0.000603	CcSEcCtD
Sorafenib—Mental disorder—Estradiol—osteoporosis	0.000138	0.000602	CcSEcCtD
Sorafenib—Dizziness—Alendronate—osteoporosis	0.000138	0.000601	CcSEcCtD
Sorafenib—Shock—Conjugated Estrogens—osteoporosis	0.000137	0.0006	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Pamidronate—osteoporosis	0.000137	0.000599	CcSEcCtD
Sorafenib—Nervous system disorder—Conjugated Estrogens—osteoporosis	0.000137	0.000598	CcSEcCtD
Sorafenib—Malnutrition—Estradiol—osteoporosis	0.000137	0.000598	CcSEcCtD
Sorafenib—Erythema—Estradiol—osteoporosis	0.000137	0.000598	CcSEcCtD
Sorafenib—Fatigue—Pamidronate—osteoporosis	0.000137	0.000598	CcSEcCtD
Sorafenib—Gastrointestinal pain—Risedronate—osteoporosis	0.000136	0.000597	CcSEcCtD
Sorafenib—Urticaria—Ethinyl Estradiol—osteoporosis	0.000136	0.000594	CcSEcCtD
Sorafenib—Constipation—Pamidronate—osteoporosis	0.000136	0.000593	CcSEcCtD
Sorafenib—Pain—Pamidronate—osteoporosis	0.000136	0.000593	CcSEcCtD
Sorafenib—Diarrhoea—Calcitriol—osteoporosis	0.000136	0.000593	CcSEcCtD
Sorafenib—Skin disorder—Conjugated Estrogens—osteoporosis	0.000136	0.000592	CcSEcCtD
Sorafenib—Body temperature increased—Ethinyl Estradiol—osteoporosis	0.000135	0.000591	CcSEcCtD
Sorafenib—Abdominal pain—Ethinyl Estradiol—osteoporosis	0.000135	0.000591	CcSEcCtD
Sorafenib—Dizziness—Raloxifene—osteoporosis	0.000135	0.000591	CcSEcCtD
Sorafenib—Vomiting—Estropipate—osteoporosis	0.000134	0.000587	CcSEcCtD
Sorafenib—Dysgeusia—Estradiol—osteoporosis	0.000134	0.000586	CcSEcCtD
Sorafenib—Dizziness—Ibandronate—osteoporosis	0.000134	0.000585	CcSEcCtD
Sorafenib—Rash—Estropipate—osteoporosis	0.000133	0.000582	CcSEcCtD
Sorafenib—Dermatitis—Estropipate—osteoporosis	0.000133	0.000581	CcSEcCtD
Sorafenib—Anorexia—Conjugated Estrogens—osteoporosis	0.000133	0.000581	CcSEcCtD
Sorafenib—Urticaria—Risedronate—osteoporosis	0.000133	0.00058	CcSEcCtD
Sorafenib—Headache—Estropipate—osteoporosis	0.000132	0.000578	CcSEcCtD
Sorafenib—Vomiting—Alendronate—osteoporosis	0.000132	0.000578	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Zoledronate—osteoporosis	0.000132	0.000577	CcSEcCtD
Sorafenib—Abdominal pain—Risedronate—osteoporosis	0.000132	0.000577	CcSEcCtD
Sorafenib—Body temperature increased—Risedronate—osteoporosis	0.000132	0.000577	CcSEcCtD
Sorafenib—Muscle spasms—Estradiol—osteoporosis	0.000132	0.000575	CcSEcCtD
Sorafenib—Rash—Alendronate—osteoporosis	0.000131	0.000573	CcSEcCtD
Sorafenib—Dermatitis—Alendronate—osteoporosis	0.000131	0.000573	CcSEcCtD
Sorafenib—Headache—Alendronate—osteoporosis	0.00013	0.00057	CcSEcCtD
Sorafenib—Vomiting—Raloxifene—osteoporosis	0.00013	0.000568	CcSEcCtD
Sorafenib—Gastrointestinal pain—Pamidronate—osteoporosis	0.00013	0.000567	CcSEcCtD
Sorafenib—Dyspnoea—Zoledronate—osteoporosis	0.000129	0.000565	CcSEcCtD
Sorafenib—Rash—Raloxifene—osteoporosis	0.000129	0.000564	CcSEcCtD
Sorafenib—Dermatitis—Raloxifene—osteoporosis	0.000129	0.000563	CcSEcCtD
Sorafenib—Vomiting—Ibandronate—osteoporosis	0.000129	0.000563	CcSEcCtD
Sorafenib—Headache—Raloxifene—osteoporosis	0.000128	0.00056	CcSEcCtD
Sorafenib—Rash—Ibandronate—osteoporosis	0.000128	0.000558	CcSEcCtD
Sorafenib—Dermatitis—Ibandronate—osteoporosis	0.000128	0.000558	CcSEcCtD
Sorafenib—Dyspepsia—Zoledronate—osteoporosis	0.000128	0.000558	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Conjugated Estrogens—osteoporosis	0.000127	0.000556	CcSEcCtD
Sorafenib—Headache—Ibandronate—osteoporosis	0.000127	0.000555	CcSEcCtD
Sorafenib—Hypersensitivity—Ethinyl Estradiol—osteoporosis	0.000126	0.000551	CcSEcCtD
Sorafenib—Vomiting—Calcitriol—osteoporosis	0.000126	0.000551	CcSEcCtD
Sorafenib—Decreased appetite—Zoledronate—osteoporosis	0.000126	0.000551	CcSEcCtD
Sorafenib—Nausea—Estropipate—osteoporosis	0.000125	0.000548	CcSEcCtD
Sorafenib—Abdominal pain—Pamidronate—osteoporosis	0.000125	0.000548	CcSEcCtD
Sorafenib—Body temperature increased—Pamidronate—osteoporosis	0.000125	0.000548	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Zoledronate—osteoporosis	0.000125	0.000547	CcSEcCtD
Sorafenib—Angioedema—Estradiol—osteoporosis	0.000125	0.000547	CcSEcCtD
Sorafenib—Rash—Calcitriol—osteoporosis	0.000125	0.000546	CcSEcCtD
Sorafenib—Fatigue—Zoledronate—osteoporosis	0.000125	0.000546	CcSEcCtD
Sorafenib—Dermatitis—Calcitriol—osteoporosis	0.000125	0.000546	CcSEcCtD
Sorafenib—Dyspnoea—Conjugated Estrogens—osteoporosis	0.000124	0.000544	CcSEcCtD
Sorafenib—Headache—Calcitriol—osteoporosis	0.000124	0.000543	CcSEcCtD
Sorafenib—Pain—Zoledronate—osteoporosis	0.000124	0.000542	CcSEcCtD
Sorafenib—Constipation—Zoledronate—osteoporosis	0.000124	0.000542	CcSEcCtD
Sorafenib—Nausea—Alendronate—osteoporosis	0.000124	0.00054	CcSEcCtD
Sorafenib—Hypersensitivity—Risedronate—osteoporosis	0.000123	0.000537	CcSEcCtD
Sorafenib—Dyspepsia—Conjugated Estrogens—osteoporosis	0.000123	0.000537	CcSEcCtD
Sorafenib—Asthenia—Ethinyl Estradiol—osteoporosis	0.000123	0.000537	CcSEcCtD
Sorafenib—Syncope—Estradiol—osteoporosis	0.000123	0.000536	CcSEcCtD
Sorafenib—Nausea—Raloxifene—osteoporosis	0.000122	0.000531	CcSEcCtD
Sorafenib—Decreased appetite—Conjugated Estrogens—osteoporosis	0.000121	0.00053	CcSEcCtD
Sorafenib—Pruritus—Ethinyl Estradiol—osteoporosis	0.000121	0.000529	CcSEcCtD
Sorafenib—ABCB1—bone marrow—osteoporosis	0.000121	0.00355	CbGeAlD
Sorafenib—Gastrointestinal disorder—Conjugated Estrogens—osteoporosis	0.00012	0.000527	CcSEcCtD
Sorafenib—Fatigue—Conjugated Estrogens—osteoporosis	0.00012	0.000526	CcSEcCtD
Sorafenib—Nausea—Ibandronate—osteoporosis	0.00012	0.000526	CcSEcCtD
Sorafenib—Loss of consciousness—Estradiol—osteoporosis	0.00012	0.000526	CcSEcCtD
Sorafenib—Asthenia—Risedronate—osteoporosis	0.00012	0.000523	CcSEcCtD
Sorafenib—Cough—Estradiol—osteoporosis	0.000119	0.000522	CcSEcCtD
Sorafenib—Constipation—Conjugated Estrogens—osteoporosis	0.000119	0.000522	CcSEcCtD
Sorafenib—Pain—Conjugated Estrogens—osteoporosis	0.000119	0.000522	CcSEcCtD
Sorafenib—Gastrointestinal pain—Zoledronate—osteoporosis	0.000119	0.000518	CcSEcCtD
Sorafenib—Hypertension—Estradiol—osteoporosis	0.000118	0.000516	CcSEcCtD
Sorafenib—Pruritus—Risedronate—osteoporosis	0.000118	0.000516	CcSEcCtD
Sorafenib—Nausea—Calcitriol—osteoporosis	0.000118	0.000515	CcSEcCtD
Sorafenib—Diarrhoea—Ethinyl Estradiol—osteoporosis	0.000117	0.000512	CcSEcCtD
Sorafenib—Hypersensitivity—Pamidronate—osteoporosis	0.000117	0.000511	CcSEcCtD
Sorafenib—Arthralgia—Estradiol—osteoporosis	0.000117	0.000509	CcSEcCtD
Sorafenib—Myalgia—Estradiol—osteoporosis	0.000117	0.000509	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Estradiol—osteoporosis	0.000116	0.000506	CcSEcCtD
Sorafenib—Urticaria—Zoledronate—osteoporosis	0.000115	0.000503	CcSEcCtD
Sorafenib—Abdominal pain—Zoledronate—osteoporosis	0.000115	0.000501	CcSEcCtD
Sorafenib—Body temperature increased—Zoledronate—osteoporosis	0.000115	0.000501	CcSEcCtD
Sorafenib—Diarrhoea—Risedronate—osteoporosis	0.000114	0.000499	CcSEcCtD
Sorafenib—Gastrointestinal pain—Conjugated Estrogens—osteoporosis	0.000114	0.000499	CcSEcCtD
Sorafenib—Dry mouth—Estradiol—osteoporosis	0.000114	0.000498	CcSEcCtD
Sorafenib—Asthenia—Pamidronate—osteoporosis	0.000114	0.000498	CcSEcCtD
Sorafenib—Dizziness—Ethinyl Estradiol—osteoporosis	0.000113	0.000495	CcSEcCtD
Sorafenib—Pruritus—Pamidronate—osteoporosis	0.000112	0.000491	CcSEcCtD
Sorafenib—Anaphylactic shock—Estradiol—osteoporosis	0.000112	0.000488	CcSEcCtD
Sorafenib—Infection—Estradiol—osteoporosis	0.000111	0.000485	CcSEcCtD
Sorafenib—Urticaria—Conjugated Estrogens—osteoporosis	0.000111	0.000485	CcSEcCtD
Sorafenib—Dizziness—Risedronate—osteoporosis	0.00011	0.000482	CcSEcCtD
Sorafenib—Abdominal pain—Conjugated Estrogens—osteoporosis	0.00011	0.000482	CcSEcCtD
Sorafenib—Body temperature increased—Conjugated Estrogens—osteoporosis	0.00011	0.000482	CcSEcCtD
Sorafenib—Shock—Estradiol—osteoporosis	0.00011	0.00048	CcSEcCtD
Sorafenib—Nervous system disorder—Estradiol—osteoporosis	0.00011	0.000479	CcSEcCtD
Sorafenib—Vomiting—Ethinyl Estradiol—osteoporosis	0.000109	0.000476	CcSEcCtD
Sorafenib—Diarrhoea—Pamidronate—osteoporosis	0.000109	0.000474	CcSEcCtD
Sorafenib—Skin disorder—Estradiol—osteoporosis	0.000108	0.000474	CcSEcCtD
Sorafenib—Rash—Ethinyl Estradiol—osteoporosis	0.000108	0.000472	CcSEcCtD
Sorafenib—Dermatitis—Ethinyl Estradiol—osteoporosis	0.000108	0.000471	CcSEcCtD
Sorafenib—Headache—Ethinyl Estradiol—osteoporosis	0.000107	0.000469	CcSEcCtD
Sorafenib—Hypersensitivity—Zoledronate—osteoporosis	0.000107	0.000467	CcSEcCtD
Sorafenib—Vomiting—Risedronate—osteoporosis	0.000106	0.000464	CcSEcCtD
Sorafenib—Rash—Risedronate—osteoporosis	0.000105	0.00046	CcSEcCtD
Sorafenib—Dermatitis—Risedronate—osteoporosis	0.000105	0.00046	CcSEcCtD
Sorafenib—Dizziness—Pamidronate—osteoporosis	0.000105	0.000459	CcSEcCtD
Sorafenib—Headache—Risedronate—osteoporosis	0.000105	0.000457	CcSEcCtD
Sorafenib—Asthenia—Zoledronate—osteoporosis	0.000104	0.000454	CcSEcCtD
Sorafenib—Hypersensitivity—Conjugated Estrogens—osteoporosis	0.000103	0.000449	CcSEcCtD
Sorafenib—Pruritus—Zoledronate—osteoporosis	0.000103	0.000448	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Estradiol—osteoporosis	0.000102	0.000445	CcSEcCtD
Sorafenib—Nausea—Ethinyl Estradiol—osteoporosis	0.000102	0.000444	CcSEcCtD
Sorafenib—Vomiting—Pamidronate—osteoporosis	0.000101	0.000441	CcSEcCtD
Sorafenib—Asthenia—Conjugated Estrogens—osteoporosis	0.0001	0.000438	CcSEcCtD
Sorafenib—Rash—Pamidronate—osteoporosis	0.0001	0.000437	CcSEcCtD
Sorafenib—Dermatitis—Pamidronate—osteoporosis	0.0001	0.000437	CcSEcCtD
Sorafenib—Dyspnoea—Estradiol—osteoporosis	9.96e-05	0.000435	CcSEcCtD
Sorafenib—Headache—Pamidronate—osteoporosis	9.94e-05	0.000434	CcSEcCtD
Sorafenib—Diarrhoea—Zoledronate—osteoporosis	9.92e-05	0.000433	CcSEcCtD
Sorafenib—Nausea—Risedronate—osteoporosis	9.91e-05	0.000433	CcSEcCtD
Sorafenib—Pruritus—Conjugated Estrogens—osteoporosis	9.87e-05	0.000432	CcSEcCtD
Sorafenib—Dyspepsia—Estradiol—osteoporosis	9.83e-05	0.00043	CcSEcCtD
Sorafenib—Decreased appetite—Estradiol—osteoporosis	9.71e-05	0.000424	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Estradiol—osteoporosis	9.64e-05	0.000421	CcSEcCtD
Sorafenib—Fatigue—Estradiol—osteoporosis	9.63e-05	0.000421	CcSEcCtD
Sorafenib—Dizziness—Zoledronate—osteoporosis	9.58e-05	0.000419	CcSEcCtD
Sorafenib—Pain—Estradiol—osteoporosis	9.55e-05	0.000417	CcSEcCtD
Sorafenib—Constipation—Estradiol—osteoporosis	9.55e-05	0.000417	CcSEcCtD
Sorafenib—Diarrhoea—Conjugated Estrogens—osteoporosis	9.55e-05	0.000417	CcSEcCtD
Sorafenib—Nausea—Pamidronate—osteoporosis	9.43e-05	0.000412	CcSEcCtD
Sorafenib—Dizziness—Conjugated Estrogens—osteoporosis	9.23e-05	0.000403	CcSEcCtD
Sorafenib—Vomiting—Zoledronate—osteoporosis	9.22e-05	0.000403	CcSEcCtD
Sorafenib—Rash—Zoledronate—osteoporosis	9.14e-05	0.000399	CcSEcCtD
Sorafenib—Gastrointestinal pain—Estradiol—osteoporosis	9.13e-05	0.000399	CcSEcCtD
Sorafenib—Dermatitis—Zoledronate—osteoporosis	9.13e-05	0.000399	CcSEcCtD
Sorafenib—Headache—Zoledronate—osteoporosis	9.08e-05	0.000397	CcSEcCtD
Sorafenib—Vomiting—Conjugated Estrogens—osteoporosis	8.87e-05	0.000388	CcSEcCtD
Sorafenib—Urticaria—Estradiol—osteoporosis	8.87e-05	0.000388	CcSEcCtD
Sorafenib—Abdominal pain—Estradiol—osteoporosis	8.83e-05	0.000386	CcSEcCtD
Sorafenib—Body temperature increased—Estradiol—osteoporosis	8.83e-05	0.000386	CcSEcCtD
Sorafenib—Rash—Conjugated Estrogens—osteoporosis	8.8e-05	0.000385	CcSEcCtD
Sorafenib—Dermatitis—Conjugated Estrogens—osteoporosis	8.79e-05	0.000384	CcSEcCtD
Sorafenib—Headache—Conjugated Estrogens—osteoporosis	8.74e-05	0.000382	CcSEcCtD
Sorafenib—Nausea—Zoledronate—osteoporosis	8.61e-05	0.000376	CcSEcCtD
Sorafenib—Nausea—Conjugated Estrogens—osteoporosis	8.29e-05	0.000362	CcSEcCtD
Sorafenib—Hypersensitivity—Estradiol—osteoporosis	8.23e-05	0.00036	CcSEcCtD
Sorafenib—Asthenia—Estradiol—osteoporosis	8.01e-05	0.00035	CcSEcCtD
Sorafenib—Pruritus—Estradiol—osteoporosis	7.9e-05	0.000345	CcSEcCtD
Sorafenib—Diarrhoea—Estradiol—osteoporosis	7.64e-05	0.000334	CcSEcCtD
Sorafenib—Dizziness—Estradiol—osteoporosis	7.39e-05	0.000323	CcSEcCtD
Sorafenib—Vomiting—Estradiol—osteoporosis	7.1e-05	0.00031	CcSEcCtD
Sorafenib—Rash—Estradiol—osteoporosis	7.04e-05	0.000308	CcSEcCtD
Sorafenib—Dermatitis—Estradiol—osteoporosis	7.04e-05	0.000307	CcSEcCtD
Sorafenib—Headache—Estradiol—osteoporosis	7e-05	0.000306	CcSEcCtD
Sorafenib—Nausea—Estradiol—osteoporosis	6.63e-05	0.00029	CcSEcCtD
Sorafenib—PDGFRA—Signaling Pathways—IRS2—osteoporosis	5.18e-06	2.74e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—SPP1—osteoporosis	5.16e-06	2.73e-05	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—MYC—osteoporosis	5.15e-06	2.73e-05	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—TGFB1—osteoporosis	5.14e-06	2.72e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—ESR1—osteoporosis	5.11e-06	2.71e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—ESR1—osteoporosis	5.11e-06	2.71e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—POMC—osteoporosis	5.1e-06	2.71e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—POMC—osteoporosis	5.1e-06	2.7e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—ADCY5—osteoporosis	5.08e-06	2.69e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism of lipids and lipoproteins—POMC—osteoporosis	5.08e-06	2.69e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—LEP—osteoporosis	5.08e-06	2.69e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—RAP1A—osteoporosis	5.07e-06	2.69e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—LEP—osteoporosis	5.06e-06	2.69e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—POMC—osteoporosis	5.05e-06	2.68e-05	CbGpPWpGaD
Sorafenib—FGFR1—Innate Immune System—IL6—osteoporosis	5.03e-06	2.67e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Innate Immune System—IL6—osteoporosis	5.02e-06	2.66e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—IL1B—osteoporosis	5.01e-06	2.65e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—P4HB—osteoporosis	5e-06	2.65e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—IL1B—osteoporosis	4.99e-06	2.65e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—CYP27A1—osteoporosis	4.98e-06	2.64e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—IL6R—osteoporosis	4.98e-06	2.64e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—IL6R—osteoporosis	4.97e-06	2.64e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—P4HB—osteoporosis	4.96e-06	2.63e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—ADCY5—osteoporosis	4.95e-06	2.63e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—GPX1—osteoporosis	4.94e-06	2.62e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—OXCT1—osteoporosis	4.94e-06	2.62e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CA2—osteoporosis	4.94e-06	2.62e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—IL6R—osteoporosis	4.93e-06	2.61e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—SPP1—osteoporosis	4.92e-06	2.61e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—ADCY5—osteoporosis	4.91e-06	2.6e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—GAPDH—osteoporosis	4.91e-06	2.6e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—IGF1—osteoporosis	4.9e-06	2.6e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—GPX1—osteoporosis	4.89e-06	2.59e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—IL6R—osteoporosis	4.87e-06	2.58e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—GAPDH—osteoporosis	4.87e-06	2.58e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—IGF1—osteoporosis	4.86e-06	2.58e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—ESR1—osteoporosis	4.85e-06	2.57e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—ACP5—osteoporosis	4.85e-06	2.57e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—ESR1—osteoporosis	4.84e-06	2.56e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—MGLL—osteoporosis	4.81e-06	2.55e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	4.79e-06	2.54e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—RAP1A—osteoporosis	4.78e-06	2.53e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—IRS1—osteoporosis	4.77e-06	2.53e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—IRS1—osteoporosis	4.77e-06	2.53e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—ADCY5—osteoporosis	4.75e-06	2.52e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—RAP1A—osteoporosis	4.74e-06	2.51e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—ENO1—osteoporosis	4.71e-06	2.5e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—IRS2—osteoporosis	4.66e-06	2.47e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PSMA2—osteoporosis	4.64e-06	2.46e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PSMA5—osteoporosis	4.64e-06	2.46e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—POMC—osteoporosis	4.6e-06	2.44e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—POMC—osteoporosis	4.6e-06	2.44e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—SPP1—osteoporosis	4.6e-06	2.44e-05	CbGpPWpGaD
Sorafenib—RAF1—Developmental Biology—IL6—osteoporosis	4.56e-06	2.42e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—LEP—osteoporosis	4.56e-06	2.42e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—MTHFR—osteoporosis	4.56e-06	2.42e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism of lipids and lipoproteins—POMC—osteoporosis	4.53e-06	2.4e-05	CbGpPWpGaD
Sorafenib—MAPK11—Gene Expression—MYC—osteoporosis	4.53e-06	2.4e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—IRS1—osteoporosis	4.53e-06	2.4e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Innate Immune System—IL6—osteoporosis	4.52e-06	2.4e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—IRS1—osteoporosis	4.52e-06	2.4e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—MTHFR—osteoporosis	4.52e-06	2.39e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—TPI1—osteoporosis	4.51e-06	2.39e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—IL1B—osteoporosis	4.5e-06	2.39e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—IL6R—osteoporosis	4.48e-06	2.38e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—IL6R—osteoporosis	4.48e-06	2.38e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—IRS2—osteoporosis	4.45e-06	2.36e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—CYP19A1—osteoporosis	4.44e-06	2.36e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—IGF1—osteoporosis	4.42e-06	2.34e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—IGF1—osteoporosis	4.42e-06	2.34e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—POMC—osteoporosis	4.36e-06	2.31e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—ESR1—osteoporosis	4.36e-06	2.31e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—LEP—osteoporosis	4.35e-06	2.31e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—POMC—osteoporosis	4.35e-06	2.31e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—CYP19A1—osteoporosis	4.34e-06	2.3e-05	CbGpPWpGaD
Sorafenib—CDK7—Disease—IL6—osteoporosis	4.33e-06	2.29e-05	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—IL6—osteoporosis	4.3e-06	2.28e-05	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—POMC—osteoporosis	4.29e-06	2.28e-05	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—POMC—osteoporosis	4.29e-06	2.28e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—IL6R—osteoporosis	4.25e-06	2.26e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—IL6R—osteoporosis	4.24e-06	2.25e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—P4HB—osteoporosis	4.24e-06	2.25e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—ENO1—osteoporosis	4.2e-06	2.23e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—IGF1—osteoporosis	4.2e-06	2.22e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—IGF1—osteoporosis	4.18e-06	2.22e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—MYC—osteoporosis	4.17e-06	2.21e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—TGFB1—osteoporosis	4.16e-06	2.2e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—GAPDH—osteoporosis	4.16e-06	2.2e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—IRS2—osteoporosis	4.16e-06	2.2e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—ESR1—osteoporosis	4.15e-06	2.2e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PSMA2—osteoporosis	4.14e-06	2.2e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PSMA5—osteoporosis	4.14e-06	2.2e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—POMC—osteoporosis	4.13e-06	2.19e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—ENO1—osteoporosis	4.1e-06	2.17e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—ADCY5—osteoporosis	4.1e-06	2.17e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—IDH2—osteoporosis	4.09e-06	2.17e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—IRS1—osteoporosis	4.07e-06	2.16e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—LEP—osteoporosis	4.07e-06	2.16e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—RAP1A—osteoporosis	4.05e-06	2.15e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PSMA5—osteoporosis	4.04e-06	2.14e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PSMA2—osteoporosis	4.04e-06	2.14e-05	CbGpPWpGaD
Sorafenib—RAF1—Innate Immune System—IL6—osteoporosis	4.03e-06	2.14e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—IL1B—osteoporosis	4.01e-06	2.13e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—SPP1—osteoporosis	3.97e-06	2.1e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—POMC—osteoporosis	3.92e-06	2.08e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—ESR1—osteoporosis	3.88e-06	2.06e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—IRS1—osteoporosis	3.88e-06	2.06e-05	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—IL6—osteoporosis	3.87e-06	2.05e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—ENO1—osteoporosis	3.86e-06	2.05e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CYP27A1—osteoporosis	3.85e-06	2.04e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—ENO1—osteoporosis	3.83e-06	2.03e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—IL6R—osteoporosis	3.82e-06	2.03e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PSMA5—osteoporosis	3.81e-06	2.02e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PSMA2—osteoporosis	3.81e-06	2.02e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—MYC—osteoporosis	3.79e-06	2.01e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—TGFB1—osteoporosis	3.78e-06	2.01e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PSMA2—osteoporosis	3.77e-06	2e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PSMA5—osteoporosis	3.77e-06	2e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—IGF1—osteoporosis	3.77e-06	2e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—CYP19A1—osteoporosis	3.76e-06	2e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—ACP5—osteoporosis	3.74e-06	1.98e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—POMC—osteoporosis	3.74e-06	1.98e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—IL6R—osteoporosis	3.65e-06	1.93e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—POMC—osteoporosis	3.64e-06	1.93e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—ADCY5—osteoporosis	3.63e-06	1.93e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—IRS1—osteoporosis	3.63e-06	1.92e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—GPX1—osteoporosis	3.62e-06	1.92e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—POMC—osteoporosis	3.61e-06	1.92e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—MYC—osteoporosis	3.6e-06	1.91e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—IGF1—osteoporosis	3.6e-06	1.91e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—TGFB1—osteoporosis	3.59e-06	1.9e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—MYC—osteoporosis	3.59e-06	1.9e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—IRS2—osteoporosis	3.59e-06	1.9e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—TGFB1—osteoporosis	3.58e-06	1.9e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—ADCY5—osteoporosis	3.55e-06	1.88e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—GPX1—osteoporosis	3.54e-06	1.88e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—POMC—osteoporosis	3.53e-06	1.87e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—MYC—osteoporosis	3.52e-06	1.86e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—LEP—osteoporosis	3.51e-06	1.86e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—TGFB1—osteoporosis	3.51e-06	1.86e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—POMC—osteoporosis	3.49e-06	1.85e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—TPI1—osteoporosis	3.48e-06	1.84e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—MYC—osteoporosis	3.43e-06	1.82e-05	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—IL6—osteoporosis	3.43e-06	1.82e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—TGFB1—osteoporosis	3.42e-06	1.81e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—IL6R—osteoporosis	3.41e-06	1.81e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—IGF1—osteoporosis	3.36e-06	1.78e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—CYP19A1—osteoporosis	3.36e-06	1.78e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—ESR1—osteoporosis	3.35e-06	1.78e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—MTHFR—osteoporosis	3.34e-06	1.77e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—CYP19A1—osteoporosis	3.28e-06	1.74e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—ENO1—osteoporosis	3.27e-06	1.74e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—P4HB—osteoporosis	3.27e-06	1.73e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—MTHFR—osteoporosis	3.26e-06	1.73e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—MYC—osteoporosis	3.24e-06	1.72e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—TGFB1—osteoporosis	3.23e-06	1.71e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PSMA2—osteoporosis	3.23e-06	1.71e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PSMA5—osteoporosis	3.23e-06	1.71e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GAPDH—osteoporosis	3.21e-06	1.7e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—IL6—osteoporosis	3.13e-06	1.66e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—IRS1—osteoporosis	3.13e-06	1.66e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—RAP1A—osteoporosis	3.13e-06	1.66e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—CYP19A1—osteoporosis	3.09e-06	1.64e-05	CbGpPWpGaD
Sorafenib—KIT—Immune System—IL6—osteoporosis	3.09e-06	1.64e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—IL6—osteoporosis	3.09e-06	1.64e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—ADCY5—osteoporosis	3.07e-06	1.63e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—GPX1—osteoporosis	3.06e-06	1.62e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—CYP19A1—osteoporosis	3.06e-06	1.62e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—POMC—osteoporosis	3.02e-06	1.6e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—MYC—osteoporosis	2.95e-06	1.56e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—IL6R—osteoporosis	2.94e-06	1.56e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—TGFB1—osteoporosis	2.94e-06	1.56e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—IL6—osteoporosis	2.93e-06	1.55e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—IL6—osteoporosis	2.92e-06	1.55e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—MYC—osteoporosis	2.92e-06	1.55e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—TGFB1—osteoporosis	2.91e-06	1.54e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—IGF1—osteoporosis	2.9e-06	1.54e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—MYC—osteoporosis	2.88e-06	1.53e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—TGFB1—osteoporosis	2.88e-06	1.53e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—IL6—osteoporosis	2.85e-06	1.51e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—MTHFR—osteoporosis	2.83e-06	1.5e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—IL6—osteoporosis	2.75e-06	1.46e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—ADCY5—osteoporosis	2.74e-06	1.46e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—GPX1—osteoporosis	2.73e-06	1.45e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—IL6—osteoporosis	2.71e-06	1.44e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—IL6—osteoporosis	2.7e-06	1.43e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—ADCY5—osteoporosis	2.68e-06	1.42e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—POMC—osteoporosis	2.67e-06	1.42e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—GPX1—osteoporosis	2.67e-06	1.42e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—MYC—osteoporosis	2.66e-06	1.41e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—MYC—osteoporosis	2.66e-06	1.41e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—TGFB1—osteoporosis	2.65e-06	1.41e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—TGFB1—osteoporosis	2.65e-06	1.41e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—IL6—osteoporosis	2.64e-06	1.4e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—IL6—osteoporosis	2.63e-06	1.4e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—CYP19A1—osteoporosis	2.62e-06	1.39e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—POMC—osteoporosis	2.61e-06	1.38e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—IL6—osteoporosis	2.58e-06	1.37e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—IL6—osteoporosis	2.57e-06	1.36e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—ENO1—osteoporosis	2.53e-06	1.34e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—ADCY5—osteoporosis	2.52e-06	1.34e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—MTHFR—osteoporosis	2.52e-06	1.34e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—MYC—osteoporosis	2.52e-06	1.34e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—GPX1—osteoporosis	2.52e-06	1.33e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—TGFB1—osteoporosis	2.52e-06	1.33e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—MYC—osteoporosis	2.51e-06	1.33e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—TGFB1—osteoporosis	2.51e-06	1.33e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—ADCY5—osteoporosis	2.5e-06	1.33e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—GPX1—osteoporosis	2.49e-06	1.32e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PSMA2—osteoporosis	2.49e-06	1.32e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PSMA5—osteoporosis	2.49e-06	1.32e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—MTHFR—osteoporosis	2.46e-06	1.31e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—IL6—osteoporosis	2.43e-06	1.29e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—IL6—osteoporosis	2.35e-06	1.24e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—MTHFR—osteoporosis	2.32e-06	1.23e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—MTHFR—osteoporosis	2.3e-06	1.22e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—MYC—osteoporosis	2.27e-06	1.2e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—POMC—osteoporosis	2.26e-06	1.2e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—TGFB1—osteoporosis	2.26e-06	1.2e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—IL6—osteoporosis	2.22e-06	1.18e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—IL6—osteoporosis	2.21e-06	1.17e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—IL6—osteoporosis	2.19e-06	1.16e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—IL6—osteoporosis	2.17e-06	1.15e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—MYC—osteoporosis	2.16e-06	1.15e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—TGFB1—osteoporosis	2.16e-06	1.14e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—ADCY5—osteoporosis	2.14e-06	1.13e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—GPX1—osteoporosis	2.13e-06	1.13e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CYP19A1—osteoporosis	2.02e-06	1.07e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—MYC—osteoporosis	2.02e-06	1.07e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—POMC—osteoporosis	2.02e-06	1.07e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—TGFB1—osteoporosis	2.01e-06	1.07e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—IL6—osteoporosis	2e-06	1.06e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—IL6—osteoporosis	2e-06	1.06e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—POMC—osteoporosis	1.97e-06	1.04e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—MTHFR—osteoporosis	1.97e-06	1.04e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—IL6—osteoporosis	1.9e-06	1.01e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—IL6—osteoporosis	1.89e-06	1e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—POMC—osteoporosis	1.86e-06	9.84e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—POMC—osteoporosis	1.84e-06	9.76e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—MYC—osteoporosis	1.74e-06	9.24e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—TGFB1—osteoporosis	1.74e-06	9.22e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—IL6—osteoporosis	1.7e-06	9.03e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—ADCY5—osteoporosis	1.65e-06	8.75e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GPX1—osteoporosis	1.64e-06	8.72e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—IL6—osteoporosis	1.62e-06	8.61e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—POMC—osteoporosis	1.57e-06	8.34e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—IL6—osteoporosis	1.52e-06	8.05e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—MTHFR—osteoporosis	1.52e-06	8.05e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—IL6—osteoporosis	1.31e-06	6.95e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—POMC—osteoporosis	1.21e-06	6.44e-06	CbGpPWpGaD
